ArticlemSphere2025
The Gcn5 lysine acetyltransferase mediates cell wall remodeling, antifungal drug resistance, and virulence of
Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Pathogenicity and virulence ofVirulence · 2026Review
- Antifungal-induced DNA dynamics and chitin remodelling across Cryptococcus spp. and the novel broad-spectrum anti-cryptococcal candidate CPTH2.Scientific reports · 2026Article
- Peroxin Pex8 couples stress responses, antifungal tolerance, and virulence regulation inAntimicrobial agents and chemotherapy · 2026Article
- Genomic insights into a clade-specificmBio · 2026Article
- Review
- The Four Critical Priority Fungi According to the World Health Organization and the Hope for New Therapies: A Focus on Cell Wall Antifungal Targets.Journal of fungi (Basel, Switzerland) · 2026Review
- Lectin-Fc(IgG) fusion proteins exhibit antifungal activity against the emerging multidrug-resistant pathogenInfection and immunity · 2025Article
- From Methylomes to CRISPR Epigenetic Editing: New Paths in Antibiotic Resistance.Pathogens (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
IMPORTANCE: Invasive fungal diseases affect approximately 6.5 million people every year, of which about 2.5 million people die worldwide. This number is expected to rise due to increasing numbers of immunosuppressed people, including the elderly, premature infants, organ transplant recipients, cancer, and HIV/AIDS patients. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have both recently emphasized a critical need for the development of new antifungal therapeutics to address expanding drug resistance among human fungal pathogens. The necessity of new antifungal drugs is also underscored by the fact that mortality due to invasive candidiasis has remained unchanged for several decades. However, the discovery of new drugs acting on antifungal drug targets is complicated because fungi are eukaryotes. This greatly limits the number of feasible fungal-specific drug targets. One class of molecules that fulfills the criterion of fungal specificity is chromatin modification enzymes such as lysine acetyltransferase (KATs). The fungal KATs are structurally less well conserved, and some modifications are only found in fungi, minimizing the risk of toxicity, thus making KATs new promising tools for antifungal therapy. We report here that Gcn5 lysine acetyltransferase mediates antifungal drug resistance and virulence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.